Salman Naseem

Salman Naseem

Auto-generated profile, based on publicly available information

Salman Naseem

Department of Medicine Rawalpindi Medical University Rawalpindi Pakistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
THTallal Mushtaq Hashmi
Tallal Mushtaq Hashmi
MAMushood Ahmed
Mushood Ahmed
Ali HaiderAli Haider
Ali Haider
SNSalman Naseem
Salman Naseem
UJUzair Jafar
Uzair Jafar
RARaheel Ahmed
Raheel Ahmed
The effectiveness of glucagon‐like peptide‐1 receptor agonists in facilitating weight loss among patients with diabetes is widely recognized. However, there are limited data available on the relative effectiveness and safety of once‐weekly semaglutide versus once‐daily liraglutide. We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024. Statistical analysis was conducted using R version 4.4.1 with the “meta” package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta‐analysis. The results indicated that OW semaglutide significantly reduced body weight (WMD: −4.55; 95% CI: −6.43, −2.67, p < 0.01), HbA1c (WMD: −0.46; 95% CI: −0.84, −0.08; p = 0.02), and fasting plasma glucose levels (WMD: −1.23; 95% CI: −1.51, −0.95; p < 0.01) in comparison to OD liraglutide. The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53–5.16; p = 0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82–4.14; p = 0.14) was comparable between both groups. Once‐weekly semaglutide therapy results in a more pronounced loss in body weight, HbA1c, and fasting glucose levels compared to once‐daily liraglutide.